Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.
Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).
Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.
Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
What is the primary focus of Geron Corporation?
What is Imetelstat?
Which conditions is Imetelstat being developed to treat?
How does Imetelstat work?
What revenue streams does Geron Corporation rely on?
Is Geron Corporation a diversified company?
What is the significance of telomerase in cancer treatment?
Has Geron Corporation achieved any significant milestones?
Where can I find the latest news about Geron Corporation?
What makes Imetelstat unique among cancer therapies?
